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A B S T R A C T
Objectives: The purpose of this study was to compare the incidence rate of invasive pneumococcal
disease, the rates of antibiotic resistance and serotype distribution among children 5 years old before
and after PCVs introduction in Casablanca, Morocco.
Methods: This study was conducted at the Ibn Rochd University Hospital Centre of Casablanca during
two periods encompassing pre-and post-implementation of PCVs, respectively from January 2007 to
October 2010 and from January 2011 to December 2014. All the non-duplicate invasive S. pneumoniae
isolates recovered during the study periods were included.
Results: There were 136 cases of IPD, 91 before and 45 after PCVs introduction. The greatest decrease in
incidence rate of IPD occurred in children  2 years of age declining from 34.6 to 13.5 per 100,000
populations (p < 0.0001) before and after vaccination, respectively. The incidence rate of PCV-7, PCV-10
non-PCV-7 and PCV-13 non-PCV-10 serotypes decrease signiﬁcantly from 18.0 to 4.6, from 5.7 to 1.3 and
from 5.7 to 0.8/100,000 population (p < 0.001) in the same age, respectively.
Conclusion: Shifts in the distribution of IPD serotypes and reductions in the incidence rate of disease
suggest an effective reduction of the burden of IPD in children, but continued high quality surveillance is
critical to assess the changes in serotype distributions.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus pneumoniae (S. pneumoniae), an encapsulated,
Gram-positive cocci, is a member of the normal upper airway ﬂora
but can cause life-threatening illnesses.1 S. pneumoniae is one of
the leading bacterial causes of community-acquired pneumonia,
acute otitis media, sinusitis, bloodstream infection (bacteraemia),
sepsis and meningitis. Invasive pneumococcal diseases (IPD) like* Corresponding author. Department of Microbiology, Faculty of Medicine and
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).meningitis and bacteraemia are major causes of morbidity and
mortality, especially among young children ( 5 years old) and
elderly adults (60 years old). Disease rates and mortality are
higher in developing than in industrialized settings, with the
majority of deaths occurring in Africa and Asia.2–3 The World
Health Organization (WHO) estimated that 1.6 million persons are
dying of pneumococcal diseases each year, of which 0.7–1 million
are children less than ﬁve years of age living in the developing
world.4
Furthermore, there has been a consistent worldwide increase in
antibiotic resistance of S. pneumoniae isolates, making therapeutic
options more difﬁcult.5 Currently, 94 capsular serotypes (grouped
into 46 serogroups based on immunologic similarities), including
the recently reported serotypes 6C, 6D, 11E, and 20A/20B, have
been identiﬁed.6–9 The serotype distribution can vary by patient
age, geographic region, and time period of surveillance. However,
many of these serotypes are rarely recovered from serious diseases,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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worldwide.10–11
Currently, there are two different types of pneumococcal
vaccines marketed: 23-valent pneumococcal polysaccharide vac-
cines (PPV-23) available since the early 1980s and pneumococcal
conjugate vaccines (PCV). The ﬁrst one of the PCVs, 7-valent PCV
(PCV-7), including capsular polysaccharides of serotypes 4, 6B, 9 V,
14, 18C, 19F, and 23F, was ﬁrst licensed in the United States (US) in
2000.12 All PCVs under development target these same seven
serotypes, but with different additional serotypes added to
subsequent formulations to expand the serotype coverage.3 For
example, PCV-7 did not include serotypes 1, 3, and 5, which are
common in Europe, Asia, and Africa.10,13 Thus, new conjugate
vaccines PCV-10 (4, 6B, 9 V, 14, 18C, 19F, 23F, 1, 5, and 7F) and
PCV-13 (4, 6B, 9 V, 14, 18C, 19F, 23F, 1, 5, 7F, 3, 6A, and 19A) have
been introduced to replace PCV-7 and expand protective coverage.
WHO recommends the inclusion of PCVs in childhood immuniza-
tion programs worldwide.4 Serotyping can be used to monitor
epidemiological trends following the introduction of serotype-
speciﬁc PCVs, which include serotypes commonly encountered in
carriage and disease.
In Morocco, the PCV-13 was introduced in the national
immunization program (NIP) in October 2010 in 2 + 1 schedule
and replaced, based on the cost, by the PCV-10 in July 2012. Before
the PCV introduction, serotypes included in PCV-10 and PCV-13
covered 71.6 and 82.4% of serotypes associated with IPD among
children under ﬁve in Casablanca, respectively.14 The objective of
this present study was to compare the incidence rate of IPD as well
as the rates of antibiotic resistance and serotype distribution
among children under ﬁve before and after PCVs introduction in
Casablanca, Morocco.
2. Materiel and methods
2.1. Study design and population
This study is based on a laboratory-based surveillance of IPD
among hospitalized children ( 5 years old) living in Casablanca. In
order to clearly analyze the target population, we stratiﬁed the
children in two age groups: children  2 years old and children >2-
5 years old. The study was conducted during two periods
encompassing pre-and post-implementation of PCVs from January
2007 to October 2010 and from January 2011 to December 2014,
respectively.
The months of November and December 2010 were arbitrarily
chosen as a transitional period. During which there was the
awareness campaign for vaccination and the distribution of
vaccination materials in the different health centers of Grand
Casablanca. We also considered these two months to allowing the
establishment of a post vaccination surveillance program at Grand
Casablanca.
The study was performed at the Microbiology Laboratory of Ibn
Rochd University Hospital Centre of Casablanca (IR-UHC), which is
a tertiary care hospital, comprising 1451 beds (this bed capacity
represents 52% of capacity management of patients living in Grand
Casablanca). In the IR-UHC, pediatric patients are managed at the
Abderrahim Harrouchi Children University Hospital, which is a
department comprising 240 beds. Additionally, the IR-UHC is the
only tertiary hospital covering the entire region of Grand
Casablanca, which is a Moroccan region located on the Atlantic
coast, west-central Morocco. This region covers an area of
1,140.54 km2. The Grand Casablanca population was estimated
4,270,750 in 2014, which represents 12.6% of the national
population of Morocco as provided by the High Commission for
Planning of the National Centre of Documentation in Morocco. In
Grand Casablanca, all cases of serious diseases such as meningitidisand complicated diseases in other hospitals are systematically
transferred to the IR-UHC. The microbiology laboratory of this
tertiary care hospital started laboratory-based surveillance of f IPD
since 1994 and it is the only laboratory of which the capacity of
pneumococcal serotyping is established in Casablanca. The
microbiology laboratory of IR-UHC collaborates strongly with
regional hospitals, clinics and private medical laboratories for
conﬁrmation of invasive pneumococcal strains and for serotyping.
For the speciﬁc target group of this study, Census data were
available for 2008, 2013 and 2014 while values estimated from a
standard curve determined by linear regression were used for
the remaining years with the population growth rate of 0.9% for the
study period.
2.2. Isolate collection
All the non-duplicate invasive S. pneumoniae isolates recovered
during the study periods were included. Isolates obtained from
normally sterile sites (cerebrospinal ﬂuid [CSF], blood, pleural
ﬂuids, and articular ﬂuids) were considered invasive. When an
isolate was recovered from CSF and blood, the case was categorized
as meningitis. S. pneumoniae isolates were identiﬁed following
standard procedures of bacteriology (i.e., a- hemolysis, optochin
susceptibility and bile solubility).
Each pneumococcal isolate is reported on a laboratory report
form including demographic and medical information on the
patient. For post-vaccination period, the vaccination history:
vaccinated or not by a PCV, number of doses was added to
describe immunization status. Data collected on the laboratory
report forms are entered on WHONET 5.6 Software.
2.3. Pneumococcal serotyping
Serogrouping was done by the checkerboard method with
Pneumotest-latex (Statens Serum Institute antisera, Copenhague,
Denmark) and serotyping was performed by Quellung capsule
swelling using Statens Serum Institute antisera (Copenhague,
Denmark).
2.4. Antimicrobial susceptibility
Antibiotic susceptibility testing was done following Clinical
Laboratory Standard Institute guidelines.15 Erythromycin, tetracy-
cline, choramphenicol and trimethoprim-sulfamethoxazole (cotri-
moxazole) were tested by disk diffusion with antibiotic disks from
Oxoid (Basingstoke, United Kingdom) on Mueller Hinton Agar
supplemented with 5% sheep blood (BioMe`rieux, Lyon, France).
Oxacillin (1 mg) was used for screening of penicillin non-susceptible
S. pneumoniae (PNSP). A minimal inhibitory concentration (MIC) for
penicillin G and ceftriaxone was determined on 5% sheep blood
Mueller Hinton agar with E-tests from Oxoid (Oxoid, Basingstoke,
UK). The breakpoints used for interpretation were those recom-
mended by the CLSI in 2012:  0.06 mg/ml and 2 mg/ml for
penicillin; for ceftriaxone,  0.5 mg/ml and 2 mg/ml for meningeal
isolates and 1 mg/ml and 4 mg/ml for non-meningeal isolates.
Quality control was conducted using S. pneumoniae ATCC 49619.
2.5. Estimation of incidence rate and statistical analysis
We estimated the annual incidence rate of IPD, vaccine and
non-vaccine serotypes per 100,000 populations by dividing the
number of laboratory conﬁrmed IPD, vaccine and non-vaccine
serotypes by the number of population of the target group
( 2 years old or >2 – 5 years) per year. Computerized data were
analyzed with WHONET5.6, EpiInfo 7 (Centers for Disease Control,
Atlanta, Georgia, USA) and Microsoft Excel. The chi square test or
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different age groups and different collection periods. Statistical
signiﬁcance was determined with 95% conﬁdence internals (CI).
Change in incidence rate between the pre- and post- vaccination
periods were assessed by calculating absolute risks reduction and
relative risks reduction (ARR and RRR).27 Differences were
considered signiﬁcant if the p-value was < 0.05.
2.6. Ethics statement
This study was approved by the Ethical committee for
biomedical research of the University Mohammed V - Soussi,
Faculty of Medicine, Pharmacy and Dental Medicine of Rabat,
Morocco. The patients/legal guardians were informed about the
study; they signed a consent form, and the study was carried out in
an anonymous way.
3. Results
3.1. Isolate information and incidence rate of IPD
The number of isolates per year, by clinical presentation, and by
age group are summarized in Table 1. A total of 136 S. pneumoniae
isolates were recovered from 136 children (sex ratio 1): there were
91 during the pre-implementation period (79 from children 
2 years old and 12 from children >2-5 years old) and 45 during the
post-implementation period (32 from children  2 years old and
13 from children >2-5 years old). The incidence rate of IPD
changed after the introduction of PCV. The overall annual incidence
rate of IPD decreased signiﬁcantly from 34.6 (95% CI, 27.8 – 43.1) to
13.5 (95% CI, 9.6 – 19.1; RRR = – 60.9%; p < 0.0001) per 100,000
populations among children  2 years of age before and after
vaccination, respectively (Table 1). The rate of IPD for the pre- and
post-vaccination period showed a non-signiﬁcant change for
children >2 - 5 years of age.
3.2. Serotype of S. pneumoniae recovered from IPD
The serotypes were determined for the 136 strains of
S. pneumoniae. The incidence rate of serotype before and afterTable 1
Sample origin and IPD incidence according to age groups before and after introduction
Age and specimen
sources
Pre-implementationa
2007-2010 no. of cases/
100,000 populations
Post-implementationb no. of cases/1
populations
2011 2012 2013 2014 To
(2
 2 years
CSFc 12.3 8.6 5.1 8.4 5.0 6
Blood 17.9 6.9 6.8 6.7 5.0 6
Pleural ﬂuid 2.2 0.0 0.0 0.0 0.0 0
Otherd 2.2 0.0 1.7 0.0 0.0 0
Total 34.6 15.4 13.6 15.1 0.0 13
> 2  5 years
CSF 0.6 0.4 0.4 0.0 0.4 0
Blood 0.5 0.4 0.4 0.4 1.2 0
Pleural ﬂuid 0.1 0.4 0.0 0.8 0.4 0
Other 0.0 0.0 0.0 0.0 0.0 0
Total 1.2 1.2 0.8 1.2 2.0 1
a Pre-vaccination periods were from January 2007 to October 2010. The year 2010 b
b Post vaccination periods were from January 2011 to December 2014.
c Cerebrospinal ﬂuid.
d Other sterile sites (articular ﬂuid, pus/tissues).
Incidences were calculated as incidence = Number of IPD cases x 100,000/population (
The Grand Casablanca population was estimated at 56,319 in 2007 and 59,993 in 2014 
5 years old.
NS: not signiﬁcant.PCV-13 and PCV-10 vaccines introduction in Casablanca (Table 2)
showed that the overall incidence rate of IPD caused by PCV-7,
PCV10-nonPCV7 serotypes and PCV13-nonPCV7 serotypes declined
signiﬁcantly among children  2 years of age from 18.0 to 4.6
(p < 0.0001); from 5.7 to 1.3 (p = 0.02) and from 5.7 to 0.8 (p = 0.003)
per 100,000 populations, respectively. In the same age group, we
observed a slight increase but non-signiﬁcant of the non-vaccine type
from 5.3 to 6.8 per 100,000 populations (RRR = + 28.6%). In children
>2 – 5 years old, weobserved a non-signiﬁcant change in PCV-7, PCV-
13 and PCV-10 serotypes according to the two periods of this study.
Overall, the leading serotypes causing IPD in children  2 years
of age were 14 (16.1%), 6B (13.9%), 19A (11.4%), 19F (8.9%), 23F
(8.9%) and 5 (7.6%) before vaccination. Only serotype 6B (18.7), 14
(12.5) and 1 (6.25) persist after vaccination for the same age group.
The major serotype isolated from children >2 – 5 years of age
were: 19F (25%) and 1(8.33%). There were no major changes in the
incidence rate of relative-vaccine and non-vaccine serotypes
before and after vaccine implementation (data not shown, see
additional ﬁle).
Analysis of the immunization status of our patients in the post-
vaccination period showed that 40% (10/25) of the children under
ﬁve received at least one dose on PCVs (Table 3) and 60% are
unvaccinated. Immunization schedule was incomplete for all
cases. Serotypes found in vaccinated children were: 6B (3), 14 (2), 1
(2), 7F (1), 3 (1) and 9 V (1). Clinical diagnosis of these vaccine
serotypes was mainly from meningitis (3), bacteraemia (3), and
pneumonia (2).
3.3. Antimicrobial resistance
The rate of resistance of pneumococcal strains isolated in the
two age groups before and after vaccine introduction is shown in
the Table 4. We observe signiﬁcant decrease of PNSP and
cotrimoxazole non-susceptible strains.
There were no signiﬁcant changes in antimicrobial resistance
rates between pre and post-vaccination periods for erythromycin,
tetracycline, chloramphenicol (p > 0.05) for the two age groups. A
signiﬁcant reduction of penicillin and cotrimoxazole non-suscep-
tible strains occurred in children under 2 years old. The proportion
changed from 50.6% to 21.9% (p = 0.005) and from 39.2% to 6.3% of pneumococcal conjugate vaccine in Casablanca (Morocco)
00,000 Baseline (2007 - 2010) vs Post period (2011-2014)
tal
011-2014)
Absolute Risk Reduction
cases/100,000
populations (95% CI)
Relative Risk Reduction %
(95% CI)
p-value
.8 5.5 (11.5 to 0.2) 44.9 (94.2 to 1.3) 0.05
.3 11.6 (18.5 to 5.4) 64.7 (100.0 to – 29.8) 0.003
.0 2.19 (5.1 to 0.1) 100.0 0.02
.04 1.8 (4.7 to 0.6) 80.7 (97.7 to 65.1) NS
.5 21.1 (30.5 to 12.3) 60.9 (88.1 to 35.5) <0.0001
.3 0.3 (1.1 to 0.4) 51.8 (87.7 to 92.8) NS
.6 0.08 (0.7 to 0.9) 15.74 (64.7 to 279.2) NS
.4 0.3 (0.2 to 0.9) 285.0 (56.9 to 335.2) NS
.0 0 (0.4 to 0.4)  NS
.3 0.06 (1.0 to 1.1) 4.5 (52.3 to 128.9) NS
egins in January 2010 and ends in October 2010.
 2 years old or 2-5 years old) during the years of surveillance at Casablanca.
for children  2 years, and 237,278 in 2007 and 252,750 in 2014 for children >2 –
Table 2
Incidence of vaccine and non-vaccine serotypes according to age groups before and after introduction of PCVs in Casablanca, Morocco
Age and serotypes Pre-implementationa
2007-2010 no. of
cases/100,000
populations
Post-implementationa 2011 - 2014
no. of cases/100,000 populations
Baseline (2007 - 2010) vs Post period (2011-2014
2011 2012 2013 2014 Total
(2011-2014)
Absolute Risk Reduction
cases/100,000
populations (95% CI)
Relative Risk
Reduction %
(95% CI)
p-value
 2 years old
PCV7 serotypesb 18.0 1.7 8.5 8.4 0.0 4.6 13.3 (20.0 to 7.3) 74.1 (100.1 to 40.8) <0.0001
PCV10-nonPCV7 serotypesc 5.7 1.7 0.0 0.0 3.3 1.3 4.4 (8.6 to 1.0) 77.7 (93.6 to 22.0) 0.02
PCV13-nonPCV10 serotypesd 5.7 1.7 1.7 0.0 0.0 0.8 4.8 (8.9 to 1.6) 85.2 (100.6 to 27.9) 0.003
Non-PCV13 serotypese 5.3 10.3 3.4 6.7 6.7 6.8 1.5 (3.2 to 6.3) 28.6 (61.1 to 100.2) NS
TOTAL 34.6 15.4 13.6 15.1 10.0 13.5 21.1 (30.5 to – 12.3) 60.9 (88.1 to 35.5) <0.0001
> 2 - 5 years old
PCV7 serotypes 0.6 0.04 0.4 0.4 0.4 0.4 0.2 (1.0 to 0.5) 53.7 (81.8 to 128.0) NS
PCV10-nonPCV7 serotypes 0.3 0.0 0.4 0.8 0.0 0.3 0.01 (0.6 to 0.6) 3.5 (80.5 to 300.7) NS
PCV13-nonPCV10 serotypes 0.2 0.08 0.0 0.0 0.0 0.2 0.01 (0.6 to 0.5) 3.5 (86.4 to 584.7) NS
Non-PCV13 serotypes 0.2 0.0 0.0 0.0 1.6 0.4 0.3 (0.2 to 0.9) 285.8 (56.9 to 335.2) NS
TOTAL 1.2 0.1 0.8 1.2 2.0 1.3 0.06 (1.0 to 1.1) 4.5 (52.3 to 128.9) NS
a Vaccination periods were 2007-2010 (pre) and 2011-2014 (post). The year 2010 begins in January 2010 and ends in October 2010.
Incidences were calculated as incidence = Number of serotype x 100,000/ populations ( 2 years old or 2 - 5 years old) during the years of surveillance at Casablanca.
The Grand Casablanca population was estimated at 56,319 in 2007 and 59,993 in 2014 for children  2 years, and 237,278 in 2007 and 252,750 in 2014 for children >2 –
5 years old.
b PCV7 vaccine serotypes are: 4, 6B, 9V, 14, 18C, 19F and 23F.
c PCV10-nonPCV7 are: 1, 5 and 7F.
d PCV13-nonPCV10 are 3, 6A and 19A.
e Non-PCV13 serotypes are: 11A/11E, 15A, 18F, 10F, 10A, 8, 2, 7A, 22F, 24F and Non-typables.
NS: not signiﬁcant.
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respectively. All the strains were susceptible to ceftriaxone.
4. Discussion
Pneumococcal disease remains the number one vaccine
preventable cause of death in children less than 5 yearsTable 3
Immunization status of children under 5 years after introduction of PCVs in
Casablanca
Years Cases Age
(month)
Serotype Immunization
status
Clinical diagnosis
2011
1 12 14 NV Meningitis
2 11 6A NV Pneumonia
3 36 6A NV Bacteraemia
4 36 3 NV Meningitis
5 3 7F 1 dose PCV13 Meningitis
6 36 14 NV Pleuro-pneumonia
2012
1 48 5 NV Septicemia
2 12 3 2 doses PCV13 Bacteraemia
3 12 6B 2 doses PCV13 Meningitis
4 24 14 NV Meningitis
5 12 9V 2 doses PCV13 Meningitis
6 1 6B NV Bacteraemia
7 36 14 NV Polytrauma
8 24 6B NV Peritonitis
2013
1 60 1 NV Pleuro-pneumonia
2 48 5 NV Pleurisy
3 6 14 2 doses PCV10 Pneumonia
4 36 14 NV Bacteraemia
5 7 6B 2 doses PCV10 Pneumonia
6 24 14 2 doses PCV13 Bacteraemia
7 1 6B NV Polytrauma
8 4 6B 1 dose PCV10 Polytrauma
2014
1 5 1 2 doses PCV10 Polytrauma
2 56 14 NV Bacteraemia
3 29 1 1 dose PCV10 Bacteraemia
NV: Not vaccinated.worldwide.16 S. pneumoniae is a constantly evolving species17
and its epidemiology is complex, since different serotypes show
different carriage and invasiveness properties1,18. The use of
vaccine for prevention of pneumococcal disease is crucial given
that PCV has proved to limit the spread of and infections caused by
resistant pneumococcal strains. The PCV-7 vaccine’s impact on IPD
is well described, but few reports exist on the additional impact of
the PCV-13 and PCV-10.
This study describes the serotype distribution and antimicro-
bial resistance of S. pneumoniae isolates collected in Casablanca
before and after PCV-13 and PCV-10 introduction in Moroccan NIP.
Vaccine coverage of PCVs vaccines in children aged to 2 years of
was estimated to 88% at the Grand Casablanca in 2014 as declared
by the observatory regional of epidemiology service of health of
Casablanca.
In the present study, which covered the period before (from
January 2007 to October 2010) and after (from January 2011 to
December 2014), we observed a change in the IPD cases since the
vaccine introduction.
As expected, the incidence rate of IPD associated with vaccine
serotype declined after vaccine implementation. The observed
decline was only signiﬁcant in children < 2 years. In fact, following
the introduction of PCVs in Casablanca, the incidence rate of IPD
declined from 34.6 to 13.5/ 100,000 populations with a reduction
of 61%. This reduction is dominated by bacteraemia cases followed
by meningitis cases, according to the Table 1.
In many countries, routine use of PCVs has dramatically
reduced the incidence of IPD, particularly among children aged 
2 years,23 as already reported in several studies.24–25 In Europe the
proportion of PCV-13 serotypes decreased from representing 76%
of IPD reported during 2004–2009 to approximately 60% in 2010.26
The same trend was found in several previously study after PCVs
vaccines implementation in Canada and South Africa.20,27
In contrast to children under 2 years old, we have not observed
incidence rate reductions in children of > 2 - 5 years (from 1.2 to
1.3/100,000 populations). The vaccination program was not fully
implemented in all Moroccan children. In fact, in October 2010 only
children  2 months was included in the vaccine program.
Table 4
Distribution of Penicillin G-, Erythromycin-,Cotrimoxazole-, Tetracycline-, Chloramphenicol- nonsusceptible (I + R) strains among children  5 years old during pre- and post-
vaccination periods in Casablanca, Morocco
Antibiotics  2 years > 2 - 5 years old
aPre-period n (%) bPost- period n (%) p-value aPre-period n (%) bPost- period n (%) p-value
Penicillin G 40 (50.6) 7 (21.9) 0.005 5 (41.7) 4 (30.8) NS
Erythromycin 13 (16.5) 8 (25.0) NS 3 (25.0) 2 (15.4) NS
Cotrimoxazole 31 (39.2) 2 (6.3) 0.0004 4 (33.3) 2 (15.4) NS
Tetracycline 25 (31.6) 7 (21.9) NS 6 (50.0) 3 (23.1) NS
Chloramphenicol 8 (10.1) 1 (3.1) NS 1 (8.3) 1 (7.7) NS
I = Intermediate, R= Resistant.
a The pre-period was from January 2007 to October 2010 (n=79 for children  2 years and n=12 for >2 - 5 years old).
b The post-period was from January 2011 to December 2014 (n=32 for children  2 years and n=13 for >2 - 5 years old).
n = number of (I + R).
The percentage were calculated as = Number of (I + R) x 100/ total number of strains.
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among children older than 2 years will be observed in the years to
come. Reductions in older age groups were also lagged in the US,33
Canada,20 United Kingdom and other European countries26 and
South Africa.27
Following the introduction of PCVs to all Grand Casablanca
provinces, all vaccine serotypes decline as previously described.19–
20 In 2012, the PCV-13 vaccine was replaced by the PCV-10 vaccine
in the Moroccan’s NIP. The effect of this latter vaccine is illustrated
in 2013 and 2014. In this study, we examined 18 months periods to
analyze PCV-13 impact on IPD. The monitoring period for the PCV-
10 vaccine, which received a decreasing trend already initiated by
the PCV-13 vaccine, was from July 2012 to December 2014. PCV-7
serotype common to the two vaccines declined signiﬁcantly from
18.0 to 4.6/ 100,000 populations in children under 2 years.
Comparing these results with the latest publication on the impact
of PCVs, we ﬁnd that our results, although with a certain
particularity, follow the same trend as in other countries. The
Canadian study on the impact of PCV-13, showed a signiﬁcant
decrease within the ﬁrst year of PCV-13 introduction in the
proportion of PCV-13 serotype among children  2 years old, from
63% to 43% (p < 0.001).22 Considering the Brazilian study on the
impact of PCV-10, it’s clearly demonstrated a signiﬁcant decrease
in the incidence rate of serotype included in the PCV-10 from
16.47 to 0.44 cases/1000 peoples.19 In South Africa, where the PCV-
13 is also used, the incidence rate of IPD in children aged of 2 years
was declined from 54.8 to 17.0 cases per 100,000 person-years.27
The impact of PCVs was least for serotype 6B and 14 and
greatest for 19A, 19F and 23F. Although the PCV-13 vaccine was
replaced in Moroccan NIP, the frequency of additional PCV-13
serotypes such as 19A, 3 and 6A remains virtually very low. The
overall incidence rate of IPD in children aged to 2-5 years old is
relatively low in Casablanca. This could be explained in part by the
type of monitoring system. Indeed, in passive surveillance, health
authorities do not stimulate reporting by reminding health care
workers to report disease or providing feedback to individual
health workers. Passive surveillance is less expensive than other
surveillance strategies, such as an active surveillance, and covers
wide areas (whole countries or provinces); however, because it
relies on an extensive network of health workers, it can be difﬁcult
to ensure completeness and timeliness of data. These statements
are considered as a limitation of this study.
The examination of vaccine status showed that 40% of vaccine
serotypes vaccine were isolated among children who received at
least one dose of PCV-10 or PCV-13 (Table 3). None of them had
completed the immunization schedule. Vaccine failure has been
reported in fully immunized children, most notably due to
serotype 3 after PCV-13, but also serotype 19A after PCV-10,
and after receipt of one dose of PCV-13.34–36 Here, we reported
vaccine failures after one or two doses of PCV. Vaccinationschedule was incomplete for all vaccine failures described in this
study. Indeed, the booster dose is performed at 12 months and
sometime many parents are struggling to make the booster dose
which may cause a decrease of immunity against vaccine
serotypes.
After vaccine use, several studies reported a substantial
increase of the non-vaccine serotype (NVS), known as serotype
replacement1,28 or no change in non-vaccine serotype incidence
rate.19 The overall serotype ﬂuctuations have been investigated are
probably multifactorial, as previously reported.14 Vaccination
likely contributes to serotype replacement by elimination of
strains targeted by the new vaccines, allowing the NVS to ﬁll the
new vacant ecological niche.29 Many studies have reported an
augmentation or diminution of the NVS after vaccine introduction
as reported by the strategic advisory group of experts on
immunization of WHO.30 For our study, there is no substantial
change on NVS incidence rate before and after vaccination, even if a
slight raise was observed after PCV-13 implementation.
One of the added beneﬁts of the PCV-13 and PCV-10
immunization programs in Casablanca has been the decline in S.
pneumoniae antibiotic resistance, most notably for the PNSP and
cotrimoxazole non-susceptible strains in children under 2 years, as
reported elsewhere.31 This is not surprising since the majority of
serotypes associated with penicillin resistance in Casablanca are
serotypes found in the PCV-10 and PCV-13 (i.e. 9 V, 6B, 14, 19A, 19F
and 23F). Antibiotic resistance in S. pneumoniae is a serious concern
globally.5 Vaccination has reduced the incidence rate of antibiotic
resistant serotypes, but we reported here, a rebound due to the
persistence of serotype 6B and 14. Based on a comparison of the
two study periods, pneumococcal isolates in children have become
less resistant to antibiotics in Casablanca, especially to penicillin
and cotrimoxazole, both in terms of rates and levels of resistance.
Apart from the signiﬁcant reduction of penicillin and cotrimox-
azole resistant strains, a reduction but no signiﬁcant occurred for
tetracycline, chloramphenicol and erythromycin resistant S.
pneumoniae as previously described.21,22,32
In some countries IPD caused by vaccine serotypes has virtually
disappeared, even in age groups not primarily targeted by the
immunization program, the indirect (herd) effect.4,25 For our study,
monitoring over a long period is required for other age groups,
including teenager, adults and elderly to study the herd effect.
The laboratory-based, passive surveillance of pneumococcal
serotype distribution may be limited by variable regional
standards, the preliminary nature of some data, the timeliness
of testing and reporting, the availability of isolates for testing, and
privacy concerns. There continues to be a need for a national
enhanced IPD surveillance program that includes the collection of
additional demographic and enhanced epidemiological patient
information to improve estimates of mortality and morbidity rates,
to determine their association with speciﬁc serotypes, and to guide
I. Diawara et al. / International Journal of Infectious Diseases 40 (2015) 95–101100intervention strategies to speciﬁc populations. This enhanced
system could also provide timely access to estimated vaccine
coverage rates and vaccine effectiveness information as previously
recommended.20
5. Conclusion
These data are the ﬁrst from Morocco examining the effects
of PCV-13 and PCV-10 on IPD. Moreover, these data are useful
because the epidemiology of IPD in developing countries differs
from that in other parts of the world. In this study, the incidence
rate of IPD among children  2 years old decreased, the vaccine
serotypes, PCV-13 and PCV-10, showed the same pattern of
evolution during the monitoring period. The IPD incidence rate
remained unchanged in children 2-5 years old. The PCVs
contributed to the decrease in the antibiotic resistance rates,
especially in PNSP and cotrimoxazole non-susceptibility strains.
Moreover, the serotypes with high resistance rate were rarely
isolated after vaccination. Continued high-quality surveillance is
critical to assess the changes in serotype distributions of
invasive and non-invasive S. pneumoniae after introduction of
PCVs.
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